The company buys in a PI3Kα and mTOR combo.
ApexOnco Front Page
Recent articles
Gilead opting against IDE397 is still good news for Ideaya.
Progression-free and overall survival data from Companion-002 are due this quarter.
Pivotal data are due soon with the Claudin18.2-targeting ADC sonesitatug vedotin.
JSKN027 will become the first ADC with this mechanism to enter human trials.
A binary Xpovio catalyst is set for March.
BeOne terminates a MUC1-targeting project.
Welireg, Padcev, and a surprise fillip for Flare.
